Welcome to LookChem.com Sign In|Join Free
  • or
HENAN SUNLAKE ENTERPRISE CORPORATIONcas:387867-13-2 C31H42N6O4//file1.lookchem.com/300w/substances/2022-02-14-05/03f87112-72b9-4f1a-be7a-ed65a4d0506d.png
qq

Communicate with Supplier:

Ms. summer
Ms. summer: What can I do for you?

cas:387867-13-2 C31H42N6O4 CAS NO.387867-13-2

Min.Order Quantity:
500 Gram
Purity:
99%
Port:
depend on clients require
Payment Terms:
L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

  • cas:387867-13-2
  • cas:387867-13-2 C31H42N6O4
  • C31H42N6O4

Quick Details

  • ProName: cas:387867-13-2 C31H42N6O4
  • CasNo: 387867-13-2
  • Molecular Formula: C31H42N6O4
  • Appearance: white poweder
  • Application: cas:387867-13-2 C31H42N6O4 technical ...
  • DeliveryTime: 3 wordking days after receive payment
  • PackAge: Plastic vacuum packaging bag or bucket
  • Port: depend on clients require
  • ProductionCapacity: 1 Kilogram/Day
  • Purity: 99%
  • Storage: under the cool and dry area
  • Transportation: by express or by sea
  • LimitNum: 500 Gram

Superiority

4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide basic information
product name: 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
synonyms: tandutinib(tinibs);(4-(6-methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-n-(4-(methylethoxy)phenyl)carboxamide;4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide;4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-n-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide;ct 53518;mln 518;tandutinib for research;tandutinib
cas: 387867-13-2
mf: c31h42n6o4
mw: 562.7
einecs:
product categories: api;intermediates & fine chemicals;pharmaceuticals;tyrosine kinase inhibitors;zubrin;inhibitors
mol file: 387867-13-2.mol
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide structure
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide chemical properties
mp 177-178°c
storage temp. refrigerator
cas database reference 387867-13-2(cas database reference)
safety information
msds information
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide usage and synthesis
chemical properties white solid
usage an oral, small-molecule inhibitor of flt3 for the treatment of aml (acute myelogenous leukemia) and other cancer indications. the drug exhibited limited activity as a single agent in phase i and ii clinical trials in patients with aml and myelody
usage antipsoratic
usage an oral, small-molecule inhibitor of flt3 for the treatment of aml (acute myelogenous leukemia) clinical trials in patients with aml and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase i/ii trial in patients with newly diagnosed aml w hen administered in combination with cytarabine and daunorubicin.

our services

1. top quality

2. competitive price

3. fast feedback

4. excellent after-sale service

5. safe delivery

our advantage

1. risk-free guarantee,15days refund

2. most of the products in stock,can ship within 2days after the order
3. stable quality and supply ability,samsung,lg,merck,dow,ge, supplier

4.iso9001,iso14001,rosh certification

5. duns registered,d-u-n-s number :530844988,give you the confidence to do business with us!

6. we can supply custom synthesis service.

ruiyuan can quickly and efficiently provide a variety of organic compounds, oled intermediates .main including: carbazole, fluorene, anthracene, boronic acid, naphthaline, thiophene, imidazole derivatives and so on. also can provide custom synthesis from the laboratory scale to commercial production.

company information

sunlake. is a research-based and customer-oriented enterprise. its professionals are dedicated to the discovery of innovative fine chemicals,specialized for organic photoconductors,intermediates of liquid crystal ,pharmaceutical ingredients,food addiitives and health products.

it’s our pleasure to support our customer to solve the mater from the product’s initial research and development to kilo lab experiments to pilot plant production and commercial stable production.

Details

4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide basic information
product name: 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
synonyms: tandutinib(tinibs);(4-(6-methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-n-(4-(methylethoxy)phenyl)carboxamide;4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide;4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-n-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide;ct 53518;mln 518;tandutinib for research;tandutinib
cas: 387867-13-2
mf: c31h42n6o4
mw: 562.7
einecs:
product categories: api;intermediates & fine chemicals;pharmaceuticals;tyrosine kinase inhibitors;zubrin;inhibitors
mol file: 387867-13-2.mol
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide structure
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide chemical properties
mp 177-178°c
storage temp. refrigerator
cas database reference 387867-13-2(cas database reference)
safety information
msds information
4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-n-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide usage and synthesis
chemical properties white solid
usage an oral, small-molecule inhibitor of flt3 for the treatment of aml (acute myelogenous leukemia) and other cancer indications. the drug exhibited limited activity as a single agent in phase i and ii clinical trials in patients with aml and myelody
usage antipsoratic
usage an oral, small-molecule inhibitor of flt3 for the treatment of aml (acute myelogenous leukemia) clinical trials in patients with aml and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase i/ii trial in patients with newly diagnosed aml w hen administered in combination with cytarabine and daunorubicin.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)